Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lacticaseibacillus rhamnosus DY801
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lacticaseibacillus rhamnosus DY801 is an investigational live biotherapeutic product, specifically a novel strain of Lactobacillus isolated from the fecal samples of rectal cancer patients who did not experience acute chemoradiotherapy-induced intestinal injury (ACRIII). This strain is being studied for its potential to mitigate ACRIII in patients undergoing chemoradiotherapy for colorectal cancer. The proposed mechanism of action involves the synthesis of methionine by the bacterium's metB gene. This microbial-derived methionine modulates the methionine metabolism in the host's gut lymphoid tissue inducer (Lti) cells. This leads to increased intracellular S-adenosylmethionine and subsequent histone H3 lysine 4 trimethylation (H3K4me3), an epigenetic modification. These changes result in the suppression of pro-inflammatory cytokines, specifically interleukin-17A (IL-17A) and interleukin-22 (IL-22), ultimately reducing the severity of intestinal injury without compromising the effectiveness of the cancer therapy. [1]
- Other names
- lacticaseibacillus rhamnosus DY801
02
Targets
IL-17A (Interleukin-17A)IL22 (Interleukin 22)
Beyond the preview
Go deeper on lacticaseibacillus rhamnosus DY801.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lacticaseibacillus rhamnosus DY801.